Although ICIs have been evaluated in NSCLC [8,9,10,11], with efficacy benefits over leading chemotherapeutics (e.g., docetaxel), adaptive resistance to PD-1/PD-L1 blockade has been documented [9]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.